Market Overview

UPDATE: Canaccord Genuity Raises PT on Biogen Idec on Tecfidera Approval

Related BIIB
Historical Biotech IPO Data From The 'Godfather Of Biotechnology'
Trans Pacific Trade Pact Finally Agreed
Acorda Soars, Settles Ampyra Patent Dispute with Allergan (Zacks)

In a report published Thursday, Canaccord Genuity analyst Ritu Baral reiterated a Buy rating on Biogen Idec (NASDAQ: BIIB), and raised the price target from $187.00 to $200.00.

In the report, Baral noted, “Reiterate BUY, increasing target to $200 on approval of Tecfidera (Tec), BIIB's new blockbuster potential oral MS drug with sparkling clean label. BIIB guidance implies strong confidence in the Tec launch. We have confidence in the initial phase of launch on high levels of community patient warehousing.We see long-term value and blockbuster potential in Tec, Tysabri and the hemophilia franchise. Our $200 price target is DCF-based.”

Biogen Idec closed on Wednesday at $182.68.

Latest Ratings for BIIB

Sep 2015Leerink SwannMaintainsOutperform
Sep 2015JefferiesInitiates Coverage onBuy
Aug 2015H.C. WainwrightInitiates Coverage onBuy

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings


Related Articles (BIIB)

View Comments and Join the Discussion!

Get Benzinga's Newsletters